Accomplishment of the 1st stage of the external growth strategy - Confirmation of DISTIMP acquisition
28 Juin 2021 - 6:14PM
Accomplishment of the 1st stage of the external growth strategy -
Confirmation of DISTIMP acquisition
Press Release
Ecully,
28 June 2021 - 6:00pm
Acquisition of the company
Distimp confirmed
Spineway, specialist in innovative
implants for the treatment of severe vertebral column
(spine) disorders, announces the
final signing to acquire 100% of the capital of
Distimp, a French player in the
spine surgery implants
sector.
This acquisition is part of the Group’s growth
strategy and allows Spineway to expand its products and services to
provide a wider range of implants and instruments for the treatment
of severe spinal disorders, as well as new operating techniques
with high added value for surgeons. This move will also enable the
Group to strengthen its commercial positions, particularly in
France, by accessing Distimp’s extensive network of spine
surgeons.
As announced, this acquisition is fully paid in
cash and sees the integration of Mr Fabrice Paccagnella, President
of Distimp, into the Spineway staff to oversee this new
subsidiary’s sales and development in the implant ranges.
Stéphane Le Roux, CEO of Spineway, stated: “We
are thrilled to join the company Distimp, which means we can
benefit from its founder’s experience of more than 25 years in the
spine sector and offer our clients new solutions in terms of spine
surgery. The commercial synergies and products that we will put in
place will also allow us to strengthen our presence on the domestic
market. This acquisition marks the accomplishment of the 1st stage
in our ambition to build a European benchmark player in the spine
sector”.
Fabrice Paccagnella, President of Distimp,
commented on the acquisition: “I am delighted to have joined forces
with with the Spineway group. The perfect complementarity between
our sales networks and our products opens up new growth prospects
with the distribution of original and innovative product ranges. I
look forward to being part of the Spineway teams and to participate
in the Group’s growth”.
Upcoming:
Turnover 1st semester 2021 - July 13, 2021
SPINEWAY IS ELIGIBLE FOR THE PEA-PME
(EQUITY SAVINGS PLANS FOR SMES)Find out all about Spineway
at www.spineway.com
This press release has been prepared in both
English and French. In case of discrepancies, the French version
shall prevail.
Spineway designs,
manufactures and markets innovative
implants and surgical instruments for treating severe disorders of
the spinal column.Spineway has an
international network of over 50 independent distributors and 90%
of its revenue comes from
exports.Spineway, which is
eligible for investment through FCPIs (French unit trusts
specializing in innovation), has received the OSEO Excellence award
since 2011 and has won the Deloitte Fast 50 award (2011). Rhône
Alpes INPI Patent Innovation award (2013) – INPI Talent award
(2015). ISIN: FR0011398874 - ALSPW
Contacts:
SPINEWAYShareholder-services
lineAvailable Tuesday through Thursday(10 a.m. – 12
p.m.)+33 (0)811 045 555 |
Eligible PEA / PMEALSPWEuronext Growth |
AELIUM Finance & CommunicationInvestor
relationsSolène Kennisspineway@aelium.fr |
- SPW_Confirmation_DISTIMP_VD_GB
Spineway (EU:ALSPW)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Spineway (EU:ALSPW)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024